Per the paper, for drug application to treat pancreatic cancer, the threshold should be lowered to 27.9%.<p>In other words, if a company wants to make money, it can randomly pick 4 non toxic compounds, and apply for FDA approval for treating of pancreatic cancer through click-trial, in average the company would get 4*0.279 ~=~ 1 compound approved and then market the medicine to the world that the medicine is effective.<p>They give weight&#x2F;cost to type I and type II error, and their whole analysis can be changed if the weights changed.<p>I would treat the paper as a research-toy, self fulfillment. Try to change policy based on the paper would be absurd.